Edition:
United States

Celgene Corp (CELG.OQ)

CELG.OQ on NASDAQ Stock Exchange Global Select Market

78.63USD
25 May 2018
Change (% chg)

$-0.91 (-1.14%)
Prev Close
$79.54
Open
$79.41
Day's High
$79.52
Day's Low
$78.34
Volume
2,208,307
Avg. Vol
2,472,935
52-wk High
$147.13
52-wk Low
$74.14

Chart for

About

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology... (more)

Overall

Beta: 1.43
Market Cap(Mil.): $56,993.16
Shares Outstanding(Mil.): 724.83
Dividend: --
Yield (%): --

Financials

  CELG.OQ Industry Sector
P/E (TTM): 15.13 29.19 33.30
EPS (TTM): 5.20 -- --
ROI: 14.31 13.53 13.04
ROE: 64.34 15.25 14.90

BRIEF-Evotec And Celgene Enter Into Strategic Oncology Partnership

* DGAP-ADHOC: EVOTEC AND CELGENE ENTER INTO STRATEGIC ONCOLOGY PARTNERSHIP

May 21 2018

Celgene profit tops estimates; clarifies path for key MS drug

Celgene Corp reported much-needed, stronger-than-expected first quarter results as profit and sales of several drugs exceeded Wall Street forecasts, and the U.S. biotechnology company said it would re-apply for approval of an important multiple sclerosis treatment in early 2019.

May 04 2018

UPDATE 3-Celgene profit tops estimates; clarifies path for key MS drug

May 4 Celgene Corp reported much-needed, stronger-than-expected first quarter results as profit and sales of several drugs exceeded Wall Street forecasts, and the U.S. biotechnology company said it would re-apply for approval of an important multiple sclerosis treatment in early 2019.

May 04 2018

CORRECTED-UPDATE 2-Celgene tops estimates on higher demand for cancer drug Revlimid

* To resubmit ozanimod marketing application earlier than expected

May 04 2018

BRIEF-Celgene Reports Q1 Adjusted Earnings Per Share Of $2.05

* CELGENE REPORTS FIRST QUARTER 2018 OPERATING AND FINANCIAL RESULTS

May 04 2018

Celgene's quarterly profit dips 9 percent

May 4 Celgene Corp's quarterly profit fell about 9 percent despite the U.S. biotech reporting higher revenue, as its expenses surged.

May 04 2018

BRIEF-Celgene Corp Entered Into An Amended And Restated Credit Agreement

* CELGENE CORP - ENTERED INTO AN AMENDED AND RESTATED CREDIT AGREEMENT TO EXTEND TERM OF CREDIT FACILITY TO APRIL 25, 2023 FROM APRIL 17, 2022 Source text (https://bit.ly/2HCsgr2) Further company coverage:

Apr 30 2018

Wall Street slides as healthcare drags but manages monthly gain

NEW YORK Wall Street fell on Monday as healthcare stocks slid and investors worried about rising costs for companies as oil prices rose, although the major indexes eked out a gain in April to snap a two-month losing streak. | Video

Apr 30 2018

BRIEF-Celgene Corp Says CEO Mark Alles's FY 2017 Total Compensation Was $13.1 Mln Vs $12.2 Mln In FY 2016

* CELGENE CORP SAYS CEO MARK ALLES'S FY 2017 TOTAL COMPENSATION WAS $13.1 MILLION VERSUS $12.2 MILLION IN FY 2016 - SEC FILING

Apr 30 2018

BRIEF-Zymeworks And Celgene Expand Bispecific Antibody Collaboration

* ZYMEWORKS AND CELGENE EXPAND BISPECIFIC ANTIBODY COLLABORATION

Apr 23 2018

Competitors

  Price Chg
Takeda Pharmaceutical Co Ltd (4502.T) ¥4,465 --
Eisai Co., Ltd (4523.T) ¥7,896 --
Johnson & Johnson (JNJ.N) $121.47 -0.78
Novartis AG (NOVN.S) CHF75.56 -0.10
Pfizer Inc. (PFE.N) $35.68 -0.21
Roche Holding Ltd. (ROG.S) CHF217.60 -1.40
Roche Holding Ltd. (RO.S) CHF221.00 -2.40
Merck & Co., Inc. (MRK.N) $59.09 -0.04
Sanofi SA (SASY.PA) €65.78 0.00
AstraZeneca plc (AZN.L) 5,478.00 +50.00

Earnings vs. Estimates